# Combined Inhibition of Dipeptidyl Peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/CD13) in the Treatment of Psoriasis

> **NCT00824980** · PHASE2 · UNKNOWN · sponsor: **Immune Technologies & Medicine GmbH** · enrollment: 24 (estimated)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** IP10.C8

## Key facts

- **NCT ID:** NCT00824980
- **Lead sponsor:** Immune Technologies & Medicine GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-01
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2009-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00824980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00824980, "Combined Inhibition of Dipeptidyl Peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/CD13) in the Treatment of Psoriasis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00824980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*